Timothée Olivier

1.7k total citations
83 papers, 873 citations indexed

About

Timothée Olivier is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Timothée Olivier has authored 83 papers receiving a total of 873 indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 23 papers in Economics and Econometrics. Recurrent topics in Timothée Olivier's work include Cancer Genomics and Diagnostics (17 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers) and Economic and Financial Impacts of Cancer (15 papers). Timothée Olivier is often cited by papers focused on Cancer Genomics and Diagnostics (17 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers) and Economic and Financial Impacts of Cancer (15 papers). Timothée Olivier collaborates with scholars based in Switzerland, United States and France. Timothée Olivier's co-authors include Vinay Prasad, Alyson Haslam, Alfredo Addeo, Giuseppe Luigi Banna, Juliette Thariat, Anna Patrikidou, Karim Fizazi, François Bertucci, Christine Le Maignan and Nicolas Penel and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Timothée Olivier

76 papers receiving 860 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Timothée Olivier Switzerland 15 463 341 123 119 99 83 873
Meredith K. Chuk United States 14 429 0.9× 260 0.8× 175 1.4× 116 1.0× 69 0.7× 29 858
Anastasios Dimou United States 16 481 1.0× 311 0.9× 201 1.6× 115 1.0× 72 0.7× 67 800
Hadar Goldvaser Israel 15 450 1.0× 185 0.5× 236 1.9× 381 3.2× 103 1.0× 71 899
Thomas J. Semrad United States 15 395 0.9× 237 0.7× 257 2.1× 162 1.4× 99 1.0× 51 890
Henrik Hellborg Sweden 18 667 1.4× 293 0.9× 337 2.7× 355 3.0× 111 1.1× 24 1.2k
Claudia Omarini Italy 14 507 1.1× 243 0.7× 184 1.5× 267 2.2× 73 0.7× 54 777
Artur Katz Brazil 15 604 1.3× 360 1.1× 204 1.7× 326 2.7× 135 1.4× 59 998
Qi Lin China 18 410 0.9× 274 0.8× 251 2.0× 204 1.7× 57 0.6× 67 927
Sukhbinder Dhesy‐Thind Canada 17 842 1.8× 263 0.8× 156 1.3× 299 2.5× 47 0.5× 50 1.3k

Countries citing papers authored by Timothée Olivier

Since Specialization
Citations

This map shows the geographic impact of Timothée Olivier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Timothée Olivier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Timothée Olivier more than expected).

Fields of papers citing papers by Timothée Olivier

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Timothée Olivier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Timothée Olivier. The network helps show where Timothée Olivier may publish in the future.

Co-authorship network of co-authors of Timothée Olivier

This figure shows the co-authorship network connecting the top 25 collaborators of Timothée Olivier. A scholar is included among the top collaborators of Timothée Olivier based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Timothée Olivier. Timothée Olivier is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Olivier, Timothée, et al.. (2025). When suboptimal post-protocol care in oncology trials is rewarded. European Journal of Cancer. 228. 115702–115702.
2.
3.
Özdemir, Berna C., Ruben Bill, Alper Okyar, et al.. (2025). Chrono-immunotherapy as a low-hanging fruit for cancer treatment? A call for pragmatic randomized clinical trials. Journal for ImmunoTherapy of Cancer. 13(3). e010644–e010644. 1 indexed citations
4.
Borgeaud, Maxime, Timothée Olivier, Jair Bar, et al.. (2025). Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management. CA A Cancer Journal for Clinicians. 75(5). 387–409. 3 indexed citations
5.
Olivier, Timothée, Alyson Haslam, & Vinay Prasad. (2024). Health-related quality of life in trials with high rates of early censoring: Caution advised. European Journal of Cancer. 205. 114105–114105. 4 indexed citations
6.
Olivier, Timothée, et al.. (2024). Bedside implications of the use of surrogate endpoints in solid and haematological cancers: implications for our reliance on PFS, DFS, ORR, MRD and more. SHILAP Revista de lepidopterología. 3(1). e000364–e000364. 1 indexed citations
7.
Borgeaud, Maxime, Kaushal Parikh, Giuseppe Luigi Banna, et al.. (2024). Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. Journal of Thoracic Oncology. 19(7). 973–983. 27 indexed citations
8.
Schulte, Brian, Caleb Hwang, Andrew Horvai, & Timothée Olivier. (2024). When destiny doesn’t pan out: Implications for the treatment of sarcomas after the agnostic approval of trastuzumab deruxtecan. Cancer. 130(23). 4020–4024. 1 indexed citations
9.
Olivier, Timothée & Vinay Prasad. (2024). Equal censoring but still informative: When the reasons for censoring differ between treatment arms. European Journal of Cancer. 201. 113942–113942. 13 indexed citations
10.
Olivier, Timothée, et al.. (2024). Progression-free survival estimates are shaped by specific censoring rules: Implications for PFS as an endpoint in cancer randomized trials. European Journal of Cancer. 202. 114022–114022. 3 indexed citations
11.
Haslam, Alyson, Timothée Olivier, & Vinay Prasad. (2023). The definition of long COVID used in interventional studies. European Journal of Clinical Investigation. 53(8). e13989–e13989. 17 indexed citations
12.
Olivier, Timothée, et al.. (2023). Eligibility for Human Leukocyte Antigen–Based Therapeutics by Race and Ethnicity. JAMA Network Open. 6(10). e2338612–e2338612. 13 indexed citations
13.
Olivier, Timothée, Claire E.P. Smith, Alyson Haslam, Alfredo Addeo, & Vinay Prasad. (2023). Quality of life in the adjuvant setting: A meta-analysis of US Food and Drug Administration approved anti-cancer drugs from 2018 to 2022. Journal of Cancer Policy. 37. 100426–100426. 3 indexed citations
14.
Jenei, Kristina, Alyson Haslam, Timothée Olivier, Miloš D. Miljković, & Vinay Prasad. (2022). What drives cancer clinical trial accrual? An empirical analysis of studies leading to FDA authorisation (2015–2020). BMJ Open. 12(10). e064458–e064458. 5 indexed citations
15.
Lythgoe, Mark P., Timothée Olivier, & Vinay Prasad. (2021). The iceberg plot, improving the visualisation of therapy response in oncology in the era of sequence-directed therapy. European Journal of Cancer. 159. 56–59. 1 indexed citations
16.
Banna, Giuseppe Luigi, Timothée Olivier, Francesco Rundo, et al.. (2019). The Promise of Digital Biopsy for the Prediction of Tumor Molecular Features and Clinical Outcomes Associated With Immunotherapy. Frontiers in Medicine. 6. 172–172. 40 indexed citations
17.
Labidi‐Galy, Sana Intidhar, Timothée Olivier, Manuel Rodrigues, et al.. (2017). Location of mutation in BRCA2 gene and survival in patients with ovarian cancer. Annals of Oncology. 28. v335–v335. 6 indexed citations
18.
Cesne, Axel Le, Isabelle Ray‐Coquard, Florence Duffaud, et al.. (2015). Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. European Journal of Cancer. 51(6). 742–750. 80 indexed citations
19.
Jonghe, Kris De, et al.. (2015). PHYTOPLASMAS IN POME FRUIT TREES: UPDATE OF THEIR PRESENCE AND THEIR VECTORS IN BELGIUM.. PubMed. 80(2). 143–8. 1 indexed citations
20.
Olivier, Timothée, et al.. (2012). First report of molecular identification of ‘Candidatus Phytoplasma pyri’ in pear trees in Belgium. New Disease Reports. 26(1). 29–29.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Meredith K. Chuk Breakdown of academic impact, for papers by Anastasios Dimou Breakdown of academic impact, for papers by Hadar Goldvaser Breakdown of academic impact, for papers by Thomas J. Semrad Breakdown of academic impact, for papers by Henrik Hellborg Breakdown of academic impact, for papers by Claudia Omarini Breakdown of academic impact, for papers by Artur Katz Breakdown of academic impact, for papers by Qi Lin Breakdown of academic impact, for papers by Sukhbinder Dhesy‐Thind
Rankless by CCL
2026